Compare Cadila Healthcare with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs JUBILANT LIFE SCIENCES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE JUBILANT LIFE SCIENCES CADILA HEALTHCARE/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 30.2 12.1 249.5% View Chart
P/BV x 3.6 2.3 159.6% View Chart
Dividend Yield % 1.0 0.7 145.0%  

Financials

 CADILA HEALTHCARE   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
CADILA HEALTHCARE/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs432898 48.2%   
Low Rs306618 49.6%   
Sales per share (Unadj.) Rs128.6572.0 22.5%  
Earnings per share (Unadj.) Rs18.536.2 51.2%  
Cash flow per share (Unadj.) Rs24.459.5 41.0%  
Dividends per share (Unadj.) Rs3.504.50 77.8%  
Dividend yield (eoy) %0.90.6 159.5%  
Book value per share (Unadj.) Rs101.5301.9 33.6%  
Shares outstanding (eoy) m1,023.74159.28 642.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.3 216.8%   
Avg P/E ratio x19.920.9 95.2%  
P/CF ratio (eoy) x15.112.7 118.9%  
Price / Book Value ratio x3.62.5 145.1%  
Dividend payout %18.912.4 151.9%   
Avg Mkt Cap Rs m378,170120,694 313.3%   
No. of employees `00012.42.4 520.4%   
Total wages/salary Rs m21,24119,260 110.3%   
Avg. sales/employee Rs Th10,585.038,120.6 27.8%   
Avg. wages/employee Rs Th1,707.88,058.4 21.2%   
Avg. net profit/employee Rs Th1,526.52,414.3 63.2%   
INCOME DATA
Net Sales Rs m131,65691,108 144.5%  
Other income Rs m2,011357 562.7%   
Total revenues Rs m133,66791,466 146.1%   
Gross profit Rs m29,73117,390 171.0%  
Depreciation Rs m5,9863,709 161.4%   
Interest Rs m1,9352,198 88.0%   
Profit before tax Rs m23,82111,840 201.2%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m5,3033,268 162.3%   
Profit after tax Rs m18,9875,770 329.1%  
Gross profit margin %22.619.1 118.3%  
Effective tax rate %22.327.6 80.7%   
Net profit margin %14.46.3 227.7%  
BALANCE SHEET DATA
Current assets Rs m84,98145,848 185.4%   
Current liabilities Rs m73,42520,897 351.4%   
Net working cap to sales %8.827.4 32.1%  
Current ratio x1.22.2 52.8%  
Inventory Days Days7557 131.2%  
Debtors Days Days11051 215.0%  
Net fixed assets Rs m133,49365,498 203.8%   
Share capital Rs m1,024159 642.8%   
"Free" reserves Rs m102,83947,930 214.6%   
Net worth Rs m103,86348,089 216.0%   
Long term debt Rs m39,49742,429 93.1%   
Total assets Rs m234,831114,685 204.8%  
Interest coverage x13.36.4 208.4%   
Debt to equity ratio x0.40.9 43.1%  
Sales to assets ratio x0.60.8 70.6%   
Return on assets %8.96.9 128.2%  
Return on equity %18.312.0 152.4%  
Return on capital %18.312.4 147.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,40412,422 389.7%   
Fx outflow Rs m11,59317,227 67.3%   
Net fx Rs m36,811-4,805 -766.1%   
CASH FLOW
From Operations Rs m28,82311,215 257.0%  
From Investments Rs m-57,387-10,118 567.2%  
From Financial Activity Rs m18,8466,574 286.7%  
Net Cashflow Rs m-7,1057,612 -93.3%  

Share Holding

Indian Promoters % 74.8 45.6 164.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 8.3 8.7 95.4%  
FIIs % 5.9 21.2 27.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 21.1 52.1%  
Shareholders   44,069 23,815 185.0%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DR. REDDYS LAB  IPCA LABS  ASTRAZENECA PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 94 Points, MoD Approves Defence Purchases, Vedanta's Delisting, and Top Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a positive note on Friday. Benchmark indices edged higher as positive developments in a coronavirus vaccine trial improved global risk sentiment.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jul 3, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS